Researchers have found that a new treatment called EP-104GI may significantly improve symptoms for people suffering from eosinophilic esophagitis (EoE), a condition that causes inflammation and difficulty swallowing. In a recent study, patients who received 20 injections of EP-104GI showed a notable reduction in the severity of their esophageal inflammation, as measured by a standardized scoring system called EREFS. This treatment helps target the esophagus directly, potentially offering a more effective solution for those affected by this increasingly common condition.

For individuals dealing with EoE, this could mean a major improvement in their quality of life. The study reported that patients receiving the full injection protocol experienced an average 65% decrease in inflammation after just 12 weeks. This improvement is crucial, as EoE affects over 450,000 people in the U.S. and can lead to severe discomfort and complications if untreated. The findings suggest that more injections lead to better outcomes, highlighting the importance of adequate treatment coverage in the esophagus.

The evidence is based on early-stage data from a Phase 1b/2a clinical trial, which evaluated the safety and effectiveness of EP-104GI in adults with confirmed EoE. While the results are promising, they are not yet definitive, as the study involved a small number of participants and further research is needed to confirm these findings in larger, randomized trials. Eupraxia Pharmaceuticals plans to release more data from the ongoing studies in the coming months, which may provide clearer insights into the treatment’s long-term benefits.

Source: globenewswire.com